Dr. Reddy's launches 1st generic of Geodon for injection

Dr. Reddy's is introducing the first generic of Pfizer's Geodon (ziprasidone mesylate for injection). The company's generic of the treatment for patients with schizophrenia and bipolar manic or mixed episodes has launched in single-dose vials of 20 mg/ml dosage strength. 

“We’re pleased to bring the first generic of ziprasidone mesylate for injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy,” Marc Kikuchi, CEO of Dr. Reddy’s North America generics. “This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment.”

The Geodon brand had a market value of approximately $21.8 million for the most recent 12 months ending in January 2020, according to IQVIA.